Across TCGA pan-cancer cohorts, RNU6ATAC29P RNA is linked to patient survival in 11 of 34 cancer types, making it the most broadly survival-associated RNU6ATAC29P data layer.
The strongest signal is observed in ovarian serous cystadenocarcinoma (OV), where higher RNU6ATAC29P RNA is associated with better disease-free survival. In most high-consensus cancer types, elevated RNU6ATAC29P expression acts as an unfavorable survival marker, although some lineages such as OV and STAD show a favorable association.
OV, ACC, and STAD are the cancer types where RNU6ATAC29P RNA most reproducibly stratifies survival.
RNA survival associations by lineage
Ranked by sampling consensus. AUC1 and AUC2 indicate survival in the high- and low-expression groups, respectively; the lower AUC marks the poorer-surviving group. p-values are from the log-rank test.